Lite Strategy, Inc. Additional Paid in Capital, Common Stock
Lite Strategy, Inc. (LITS) had Additional Paid in Capital, Common Stock of $521.13 million as of 2026-03-31, per its 10-Q filed 2026-05-13.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-05-13
- 2026-03-31: Additional Paid in Capital, Common Stock $521.13M.
- 2025-12-31: Additional Paid in Capital, Common Stock $520.65M.
- 2025-09-30: Additional Paid in Capital, Common Stock $520.07M.
- 2025-06-30: Additional Paid in Capital, Common Stock $421.10M.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2026-03-31 | $521.13M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $520.65M 10-Q · filed 2026-02-17 |
| 2025-09-30 | $520.07M 10-Q · filed 2025-11-14 |
| 2025-06-30 | $421.10M 10-Q · filed 2026-05-13 |
| 2025-03-31 | $421.02M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $421.00M 10-Q · filed 2025-02-12 |
| 2024-09-30 | $421.10M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $421.24M 10-K · filed 2025-09-26 |
| 2024-03-31 | $420.84M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $420.17M 10-Q · filed 2024-02-13 |
| 2023-09-30 | $430.98M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $430.62M 10-K · filed 2024-09-19 |
| 2023-03-31 | $430.32M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $428.90M 10-Q · filed 2023-02-09 |
| 2022-09-30 | $428.09M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $426.57M 10-K · filed 2023-09-26 |
| 2022-03-31 | $425.90M 10-Q · filed 2022-05-23 |
| 2021-12-31 | $422.70M 10-Q/A · filed 2022-05-23 |
| 2021-09-30 | $371.52M 10-Q/A · filed 2022-05-23 |
| 2021-06-30 | $369.17M 10-K · filed 2022-09-08 |
| 2021-03-31 | $367.06M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $364.28M 10-Q · filed 2021-02-04 |
| 2020-09-30 | $361.65M 10-Q · filed 2020-11-10 |
| 2020-06-30 | $355.45M 10-K/A · filed 2022-05-23 |
| 2020-03-31 | $333.26M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $331.71M 10-Q · filed 2020-02-06 |
| 2019-09-30 | $281.49M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $279.15M 10-K · filed 2020-09-09 |
| 2019-03-31 | $272.15M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $270.39M 10-Q · filed 2019-02-07 |
| 2018-09-30 | $268.70M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $264.86M 10-K · filed 2019-08-28 |
| 2018-03-31 | $228.06M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $227.56M 10-Q · filed 2018-02-08 |
| 2017-09-30 | $226.69M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $225.17M 10-K · filed 2018-08-30 |
| 2017-03-31 | $224.89M 10-Q · filed 2017-05-04 |
| 2016-12-31 | $224.28M 10-Q · filed 2017-02-08 |
| 2016-09-30 | $223.60M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $218.65M 10-K · filed 2017-09-05 |
| 2016-03-31 | $218.14M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $217.50M 10-Q · filed 2016-02-05 |
| 2015-09-30 | $216.70M 10-Q · filed 2015-11-06 |
| 2015-06-30 | $215.93M 10-K · filed 2016-09-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |